AU2019241339B2 - Anti-PD-L1 antibodies and uses thereof - Google Patents

Anti-PD-L1 antibodies and uses thereof Download PDF

Info

Publication number
AU2019241339B2
AU2019241339B2 AU2019241339A AU2019241339A AU2019241339B2 AU 2019241339 B2 AU2019241339 B2 AU 2019241339B2 AU 2019241339 A AU2019241339 A AU 2019241339A AU 2019241339 A AU2019241339 A AU 2019241339A AU 2019241339 B2 AU2019241339 B2 AU 2019241339B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
antibody
fragment
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019241339A
Other languages
English (en)
Other versions
AU2019241339A1 (en
Inventor
Lei Fang
Bingshi GUO
Yongqiang Wang
Zhengyi WANG
Jingwu Zang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
I Mab Biopharma Co Ltd
Original Assignee
I Mab Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Co Ltd filed Critical I Mab Biopharma Co Ltd
Publication of AU2019241339A1 publication Critical patent/AU2019241339A1/en
Assigned to I-MAB BIOPHARMA US LIMITED reassignment I-MAB BIOPHARMA US LIMITED Request for Assignment Assignors: I-MAB
Application granted granted Critical
Publication of AU2019241339B2 publication Critical patent/AU2019241339B2/en
Assigned to I-MAB BIOPHARMA CO., LTD. reassignment I-MAB BIOPHARMA CO., LTD. Request for Assignment Assignors: I-MAB BIOPHARMA US LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019241339A 2018-03-29 2019-03-29 Anti-PD-L1 antibodies and uses thereof Active AU2019241339B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/081079 2018-03-29
CN2018081079 2018-03-29
PCT/CN2019/080458 WO2019185029A1 (en) 2018-03-29 2019-03-29 Anti-pd-l1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2019241339A1 AU2019241339A1 (en) 2019-11-14
AU2019241339B2 true AU2019241339B2 (en) 2021-08-12

Family

ID=68060946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019241339A Active AU2019241339B2 (en) 2018-03-29 2019-03-29 Anti-PD-L1 antibodies and uses thereof

Country Status (18)

Country Link
US (2) US11220546B2 (es)
EP (1) EP3589660A4 (es)
JP (1) JP7124257B2 (es)
KR (2) KR102475106B1 (es)
CN (1) CN110891975B (es)
AU (1) AU2019241339B2 (es)
BR (1) BR112020019827A2 (es)
CA (1) CA3086434C (es)
CL (1) CL2020002223A1 (es)
EA (1) EA202091590A1 (es)
IL (1) IL275734B (es)
MX (1) MX2020007842A (es)
MY (1) MY188237A (es)
PE (1) PE20210377A1 (es)
PH (1) PH12020551173A1 (es)
SG (1) SG11202006008WA (es)
UA (1) UA125918C2 (es)
WO (1) WO2019185029A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126905C2 (uk) * 2016-06-13 2023-02-22 Ай-Маб Байофарма Юес Лімітед Антитіло до pd-l1 та його застосування
US11034771B2 (en) * 2018-07-25 2021-06-15 I-Mab Biopharma Us Limited Anti-CD73 anti-PD-L1 bispecific antibodies
US20220363763A1 (en) * 2018-08-21 2022-11-17 Abl Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
US20230174649A1 (en) * 2020-04-30 2023-06-08 I-Mab Biopharma Us Limited Pharmaceutical compositions containing anti-cd47 antibodies
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN114316045A (zh) * 2020-09-29 2022-04-12 锋宏生物医药科技(昆山)有限公司 抗pd-l1抗体及其用途
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
JP2024503395A (ja) * 2021-01-08 2024-01-25 北京韓美薬品有限公司 Pd-l1と特異的に結合する抗体及びその抗原結合フラグメント
TW202346366A (zh) * 2022-04-02 2023-12-01 大陸商和鉑醫藥(上海)有限責任公司 標靶pd-l1和cd40的抗原結合蛋白及其製備和應用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215590A1 (en) * 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2011043194A1 (en) 2009-10-09 2011-04-14 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device and method for manufacturing the same
CN110156892B (zh) * 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
SI3789402T1 (sl) * 2014-11-20 2022-10-28 F. Hoffmann-La Roche Ag Kombinirano zdravljenje z bispecifičnimi molekulami, ki vežejo antigen in aktivirajo celice T, ter antagonisti za vezavo osi PD-1
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CN107488229B (zh) 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
CN108777906B (zh) 2018-06-25 2020-06-16 珠海惠尔益电子科技有限公司 一种双灯组变焦电路及头灯
US11034771B2 (en) * 2018-07-25 2021-06-15 I-Mab Biopharma Us Limited Anti-CD73 anti-PD-L1 bispecific antibodies
BR112021010402A2 (pt) * 2018-11-30 2021-08-24 Abl Bio Inc. Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215590A1 (en) * 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof

Also Published As

Publication number Publication date
KR20200130747A (ko) 2020-11-19
CL2020002223A1 (es) 2021-01-29
EA202091590A1 (ru) 2021-01-21
KR102475106B1 (ko) 2022-12-08
MX2020007842A (es) 2020-09-25
KR102177931B1 (ko) 2020-11-13
WO2019185029A1 (en) 2019-10-03
JP2020518233A (ja) 2020-06-25
IL275734B (en) 2022-06-01
CN110891975A (zh) 2020-03-17
US20220119531A1 (en) 2022-04-21
IL275734A (en) 2020-08-31
CA3086434A1 (en) 2019-10-03
KR20190128716A (ko) 2019-11-18
SG11202006008WA (en) 2020-07-29
PH12020551173A1 (en) 2021-05-31
CA3086434C (en) 2024-01-09
UA125918C2 (uk) 2022-07-06
EP3589660A4 (en) 2021-04-07
JP7124257B2 (ja) 2022-08-24
BR112020019827A2 (pt) 2021-01-05
US11220546B2 (en) 2022-01-11
US20200157222A1 (en) 2020-05-21
CN110891975B (zh) 2023-11-10
PE20210377A1 (es) 2021-03-02
AU2019241339A1 (en) 2019-11-14
MY188237A (en) 2021-11-24
EP3589660A1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
US11613577B2 (en) Anti-CD73 antibodies and uses thereof
US11098118B2 (en) Anti-claudin 18.2 antibodies and uses thereof
AU2019241339B2 (en) Anti-PD-L1 antibodies and uses thereof
WO2017215590A1 (en) Anti-pd-l1 antibodies and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: I-MAB BIOPHARMA US LIMITED

Free format text: FORMER APPLICANT(S): I-MAB

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: I-MAB BIOPHARMA CO., LTD.

Free format text: FORMER OWNER(S): I-MAB BIOPHARMA US LIMITED